Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model.

doi:10.1016/j.bbrc.2020.11.110

Article

Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model.

Biochemical and biophysical research communications - 1 Jan 2021

Kobayashi Keigo, Terai Hideki, Yasuda Hiroyuki, Hamamoto Junko, Hayashi Yuichiro, Takeuchi Osamu, Mitsuishi Yoichiro, Masuzawa Keita, Manabe Tadashi, Ikemura Shinnosuke, Kawada Ichiro, Suzuki Yukio, Soejima Kenzo, Fukunaga Koichi

Abstract excerpt

The development of molecular targeted therapy has improved clinical outcomes in patients with life-threatening advanced lung cancers with driver oncogenes. However, selective treatment for KRAS-mutant lung cancer remains underdeveloped. We have successfully characterised specific molecular and pathological features of KRAS-mutant lung cancer utilising newly developed cell line models that can elucidate the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model.

Abstract excerpt

Topics

Related research